MyndTec (XCNQ:MYTC) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MyndTec Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


XCNQ:MYTC vs ABT, SYK, MDT: Short Interest Comparison

For the Medical Devices subindustry, MyndTec's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MyndTec Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MyndTec's Short Interest distribution charts can be found below:

* The bar in red indicates where MyndTec's Short Interest falls into.



MyndTec Business Description

Address 1900 Minnesota Court, Suite 122, Mississauga, ON, CAN, L5N 3C9
MyndTec Inc is a medical technology company. It researches, develops, and distributes new therapies designed to improve function, maximize independence and enhance the quality of life for individuals with upper limb paralysis due to stroke, spinal cord injury, or traumatic brain injury. The firm develops non-invasive neurological and nervous system electrical stimulation therapeutics for the treatment of neurological diseases and injuries specifically targeted to markets with large, growing, and patient populations. The company generates revenues from sales in Canada and the United States.